NASDAQ:ACON Aclarion Q2 2024 Earnings Report $2.36 0.00 (0.00%) As of 12:27 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aclarion EPS ResultsActual EPS-$1,356.75Consensus EPS -$1,718.55Beat/MissBeat by +$361.80One Year Ago EPSN/AAclarion Revenue ResultsActual Revenue$0.01 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAclarion Announcement DetailsQuarterQ2 2024Date8/14/2024TimeDuring Market HoursConference Call DateTuesday, August 13, 2024Conference Call Time6:00PM ETUpcoming EarningsAclarion's Q3 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Aclarion Earnings HeadlinesAclarion (ACON) Expected to Announce Quarterly Earnings on ThursdayAugust 6 at 2:26 AM | americanbankingnews.comAclarion’s Nociscan Expands to Goodman Campbell Brain & Spine in First Indiana SiteAugust 4 at 7:31 AM | quiverquant.comQALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.August 6 at 1:00 AM | Brownstone Research (Ad)Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the TechnologyAugust 4 at 7:00 AM | globenewswire.comAclarion, Inc.: Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026July 29, 2026 | finanznachrichten.deAclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026July 29, 2026 | globenewswire.comSee More Aclarion Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email. Email Address About AclarionAclarion (NASDAQ:ACON), a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.View Aclarion ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boeing's Comeback Is Building Momentum—Is It Real?Bed Bath & Beyond Renovates: The Neighborhood BlueprintSpaceX: Love the Company, But the Stock Is a Harder CallAstera Labs' Post-Earnings Pullback May Be Last Chance to Buy Below $360Why Analysts Are Bullish on a Stock That's Down 20%Amprius Technologies Validates Growth Trajectory With Q2 Earnings—What Comes Next?AMD’s Post-Earnings Drop May Be the Opportunity Investors Wanted Upcoming Earnings Barrick Mining (8/10/2026)Simon Property Group (8/10/2026)SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)Nebius Group (8/12/2026)NetEase (8/13/2026)Brookfield (8/13/2026)NU (8/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
